

# Martijn G H Van Oijen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1387821/publications.pdf>

Version: 2024-02-01

86  
papers

2,025  
citations

236925

25  
h-index

276875

41  
g-index

87  
all docs

87  
docs citations

87  
times ranked

3734  
citing authors

#	ARTICLE	IF	CITATIONS
1	Surveillance of Barrett's Esophagus and Mortality from Esophageal Adenocarcinoma: A Population-Based Cohort Study. <i>American Journal of Gastroenterology</i> , 2014, 109, 1215-1222.	0.4	135
2	Frequent Use of Antibiotics Is Associated with Colorectal Cancer Risk: Results of a Nested Caseâ€“Control Study. <i>Digestive Diseases and Sciences</i> , 2016, 61, 255-264.	2.3	96
3	Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer. <i>European Journal of Cancer</i> , 2015, 51, 2553-2561.	2.8	95
4	The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw166.	6.3	88
5	Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 199-206.	7.3	86
6	Explaining persistent under-use of colonoscopic cancer screening in African Americans: A systematic review. <i>Preventive Medicine</i> , 2015, 71, 40-48.	3.4	74
7	Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 549-555.	1.3	70
8	Prospective Dutch colorectal cancer cohort: an infrastructure for long-term observational, prognostic, predictive and (randomized) intervention research. <i>Acta OncolÃ³gica</i> , 2016, 55, 1273-1280.	1.8	62
9	Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: A costâ€“effectiveness analysis. <i>International Journal of Cancer</i> , 2011, 128, 1908-1917.	5.1	58
10	Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative. <i>Acta OncolÃ³gica</i> , 2018, 57, 195-202.	1.8	55
11	Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 429-441.	5.9	53
12	Reassessment of the predictive value of the Forrest classification for peptic ulcer rebleeding and mortality: can classification be simplified?. <i>Endoscopy</i> , 2013, 46, 46-52.	1.8	52
13	Risk factors of work disability in patients with inflammatory bowel disease â€” A Dutch nationwide web-based survey. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 590-597.	1.3	52
14	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. <i>Lancet Oncology</i> , The, 2018, 19, e151-e160.	10.7	51
15	High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: Results of a meta-analysis of clinical trials. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2190-2198.	1.9	43
16	Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial. <i>British Journal of Cancer</i> , 2020, 122, 634-639.	6.4	40
17	High prevalence of fatigue in inflammatory bowel disease: A case control study. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 332-337.	1.3	39
18	Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 439-456.	5.9	39

#	ARTICLE	IF	CITATIONS
19	The Use of (Network) Meta-Analysis in Clinical Oncology. <i>Frontiers in Oncology</i> , 2019, 9, 822.	2.8	38
20	Coffee and tea consumption, genotype-based <i>CYP1A2</i> and <i>NAT2</i> activity and colorectal cancer risk-Results from the EPIC cohort study. <i>International Journal of Cancer</i> , 2014, 135, 401-412.	5.1	35
21	The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis. <i>Gastric Cancer</i> , 2016, 19, 696-712.	5.3	35
22	A Nationwide Population-Based Study on the Survival of Patients with Pancreatic Neuroendocrine Tumors in The Netherlands. <i>World Journal of Surgery</i> , 2018, 42, 490-497.	1.6	32
23	A Rule for Determining Risk of Colorectal Cancer in Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 148-154.e1.	4.4	30
24	Burden of spousal caregivers of stage II and III esophageal cancer survivors 3Âyears after treatment with curative intent. <i>Supportive Care in Cancer</i> , 2015, 23, 3589-3598.	2.2	29
25	Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real-world evidence study. <i>International Journal of Cancer</i> , 2020, 146, 1889-1901.	5.1	29
26	Quality of Life During Palliative Systemic Therapy for Esophagogastric Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 12-29.	6.3	25
27	Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2017, 75, 204-212.	2.8	24
28	Volume-outcome relation in palliative systemic treatment of metastatic oesophagogastric cancer. <i>European Journal of Cancer</i> , 2017, 78, 28-36.	2.8	24
29	Gender Differences in Treatment Allocation and Survival of Advanced Gastroesophageal Cancer: A Population-Based Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1551-1560.	6.3	23
30	Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis. <i>International Journal of Cancer</i> , 2018, 143, 438-448.	5.1	22
31	Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis. <i>Scientific Reports</i> , 2017, 7, 7142.	3.3	20
32	A risk-profiling approach for surveillance of inflammatory bowel disease-colorectal carcinoma is more cost-effective: a comparative cost-effectiveness analysis between international guidelines. <i>Gastrointestinal Endoscopy</i> , 2014, 80, 842-848.	1.0	18
33	Risk of post-colonoscopy colorectal cancer due to incomplete adenoma resection: A nationwide, population-based cohort study. <i>United European Gastroenterology Journal</i> , 2017, 5, 440-447.	3.8	18
34	Metformin Use During Treatment of Potentially Curable Esophageal Cancer Patients is not Associated with Better Outcomes. <i>Annals of Surgical Oncology</i> , 2015, 22, 766-771.	1.5	17
35	Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 530.	3.7	17
36	The dynamics of HER2 status in esophageal adenocarcinoma. <i>Oncotarget</i> , 2018, 9, 26787-26799.	1.8	17

#	ARTICLE	IF	CITATIONS
37	Comparison of cecal intubation and adenoma detection between hospitals can provide incentives to improve quality of colonoscopy. <i>Endoscopy</i> , 2015, 47, 703-709.	1.8	16
38	Variation in palliative care of esophageal cancer in clinical practice: factors associated with treatment decisions. <i>Ecological Management and Restoration</i> , 2016, 30, n/a-n/a.	0.4	16
39	Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study. <i>Gastric Cancer</i> , 2020, 23, 579-590.	5.3	16
40	Value redefined for inflammatory bowel disease patients: a choice-based conjoint analysis of patients' preferences. <i>Quality of Life Research</i> , 2017, 26, 455-465.	3.1	15
41	Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review. <i>Gastric Cancer</i> , 2018, 21, 183-195.	5.3	15
42	Cachexia and Dietetic Interventions in Patients With Esophagogastric Cancer: A Multicenter Cohort Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 144-152.	4.9	15
43	Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102975.	4.4	14
44	Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): a multicenter stepped-wedge cluster randomized controlled trial. <i>Trials</i> , 2020, 21, 334.	1.6	14
45	Colectomy with Permanent End Ileostomy Is More Cost-Effective than Ileal Pouch-Anal Anastomosis for Crohn's Colitis. <i>Digestive Diseases and Sciences</i> , 2016, 61, 550-559.	2.3	13
46	Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis. <i>Acta Oncologica</i> , 2018, 57, 1599-1604.	1.8	13
47	Are we SHARP enough? The importance of adequate patient selection in sorafenib treatment for hepatocellular carcinoma. <i>Acta Oncologica</i> , 2018, 57, 1467-1474.	1.8	13
48	Cachexia, dietetic consultation, and survival in patients with pancreatic and periampullary cancer: A multicenter cohort study. <i>Cancer Medicine</i> , 2020, 9, 9385-9395.	2.8	12
49	ABC-Transporter Expression Does Not Correlate with Response to Irinotecan in Patients with Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2015, 6, 1079-1086.	2.5	11
50	Detection of palisade vessels as a landmark for Barrett's esophagus in a Western population. <i>Journal of Gastroenterology</i> , 2016, 51, 682-690.	5.1	11
51	Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 82-94.	4.4	11
52	Conversion of a colorectal cancer guideline into clinical decision trees with assessment of validity. <i>International Journal for Quality in Health Care</i> , 2021, 33, .	1.8	11
53	Implementation of real-time probe-based confocal laser endomicroscopy (pCLE) for differentiation of colorectal polyps during routine colonoscopy. <i>Endoscopy International Open</i> , 2017, 05, E1104-E1110.	1.8	10
54	Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials. <i>British Journal of Cancer</i> , 2017, 117, 1768-1776.	6.4	10

#	ARTICLE	IF	CITATIONS
55	COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 684.	2.8	10
56	Discordance in HER2 Status in Gastro-esophageal Adenocarcinomas: A Systematic Review and Meta-analysis. <i>Scientific Reports</i> , 2017, 7, 3135.	3.3	9
57	TOXview: a novel graphical presentation of cancer treatment toxicity profiles. <i>Acta OncolÃ³gica</i> , 2019, 58, 1138-1148.	1.8	9
58	From presentation to paper: Gender disparities in oncological research. <i>International Journal of Cancer</i> , 2020, 146, 3011-3021.	5.1	9
59	Improving clinical management of colon cancer through CONNECTION, a nation-wide colon cancer registry and stratification effort (CONNECTION II trial): rationale and protocol of a single arm intervention study. <i>BMC Cancer</i> , 2020, 20, 776.	2.6	9
60	Prognostic value of patient-reported quality of life for survival in oesophagogastric cancer: analysis from the population-based POCOP study. <i>Gastric Cancer</i> , 2021, 24, 1203-1212.	5.3	9
61	Left/Right Pain Asymmetry With Injectable Cosmetic Treatments for the Face. <i>Aesthetic Surgery Journal</i> , 2017, 37, 708-714.	1.6	7
62	Gastro-oesophageal junction: to FLOT or to CROSS?. <i>Acta OncolÃ³gica</i> , 2020, 59, 233-236.	1.8	7
63	The association between wearable activity monitor metrics and performance status in oncology: a systematic review. <i>Supportive Care in Cancer</i> , 2021, 29, 7085-7099.	2.2	7
64	Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer. <i>BMC Cancer</i> , 2022, 22, 394.	2.6	7
65	Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study). <i>Cancers</i> , 2019, 11, 827.	3.7	6
66	Practice variation on hospital level in the systemic treatment of metastatic colorectal cancer in The Netherlands: a population-based study. <i>Acta OncolÃ³gica</i> , 2020, 59, 395-403.	1.8	6
67	External Validation of the Dutch SOURCE Survival Prediction Model in Belgian Metastatic Oesophageal and Gastric Cancer Patients. <i>Cancers</i> , 2020, 12, 834.	3.7	6
68	Cutaneous Toxicity After Chemoradiotherapy and PD-1 Inhibition in Two Patients with Esophageal Adenocarcinoma: More than Meets the Eye. <i>Oncologist</i> , 2019, 24, e149-e153.	3.7	5
69	Modeling Personalized Adjuvant Treatment in Early stage colon cancer (PATTERN). <i>European Journal of Health Economics</i> , 2020, 21, 1059-1073.	2.8	5
70	The impact of cancer treatment on quality of life in patients with pancreatic and periampullary cancer: a propensity score matched analysis. <i>Hpb</i> , 2022, 24, 443-451.	0.3	5
71	S-1 with leucovorin and oxaliplatin for advanced gastric cancer. <i>Lancet Oncology</i> , The, 2016, 17, e41.	10.7	4
72	Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 240.	2.4	4

#	ARTICLE	IF	CITATIONS
73	Practice Variation in the Adjuvant Treatment of Colon Cancer in the Netherlands: A Population-based Study. <i>Anticancer Research</i> , 2020, 40, 4331-4341.	1.1	4
74	The first steps in the evaluation of a "black-box" decision support tool: a protocol and feasibility study for the evaluation of Watson for Oncology. <i>Journal of Clinical and Translational Research</i> , 2018, 3, 411-423.	0.3	4
75	Development and external validation of a prediction model for overall survival after resection of distal cholangiocarcinoma. <i>British Journal of Cancer</i> , 2022, 126, 1280-1288.	6.4	4
76	Cost-effectiveness in colorectal cancer: challenges on quality and comparability. <i>Colorectal Cancer</i> , 2016, 5, 21-31.	0.8	3
77	Two novel registry-based prediction models for overall survival in patients with metastatic esophageal or gastric cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4021-4021.	1.6	3
78	Diversity of first-line palliative systemic treatments for esophagogastric cancer patients with synchronous metastases: A real world evidence study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4064-4064.	1.6	2
79	Real-time diagnostic accuracy of blue light imaging, linked color imaging and white-light endoscopy for colorectal polyp characterization. <i>Endoscopy International Open</i> , 2022, 10, E9-E18.	1.8	2
80	Delayed versus immediate start of chemotherapy in asymptomatic patients with metastatic cancer: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 12126-12126.	1.6	1
81	Comprehensive ambulatory monitoring during immunotherapy in patients with advanced melanoma: A prospective trial (CAMP-IT).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS1589-TPS1589.	1.6	0
82	First-line doublet or triplet chemotherapy for advanced esophagogastric cancer: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15090-e15090.	1.6	0
83	Content evaluation of Watson for Oncology: A feasibility study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 325-325.	1.6	0
84	Practice variation on hospital level in the systemic treatment of metastatic colorectal cancer in the Netherlands: A population-based study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6612-6612.	1.6	0
85	Keeping track of all ongoing colorectal cancer trials using a mobile application: Usability and satisfaction results of the Dutch Colorectal Cancer Group Trials application. <i>Journal of Clinical and Translational Research</i> , 2018, 3, 435-440.	0.3	0
86	Physical activity levels in patients with melanoma during treatment with immune checkpoint inhibitors: Fitbit results from the CAMP-IT trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, e13610-e13610.	1.6	0